{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,8]],"date-time":"2026-06-08T15:57:52Z","timestamp":1780934272824,"version":"3.54.1"},"reference-count":27,"publisher":"American Medical Association (AMA)","issue":"6","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["JAMA Neurol"],"published-print":{"date-parts":[[2026,6,1]]},"abstract":"\n Importance<\/jats:title>\n Multiple trials have found no difference in secondary stroke prevention between anticoagulation and antiplatelet therapy after cryptogenic stroke. Due to limitations of current stroke mechanism classification, one possible explanation is the failure to exclude patients with hypertension-related cerebrovascular disease.<\/jats:p>\n <\/jats:sec>\n \n Objective<\/jats:title>\n To determine whether hypertension with high-risk features is associated with treatment effect modification of anticoagulation vs antiplatelet therapy.<\/jats:p>\n <\/jats:sec>\n \n Design, Setting, and Participants<\/jats:title>\n This exploratory analysis of the Apixaban to Prevent Recurrence After Cryptogenic Stroke in Patients With Atrial Cardiopathy (ARCADIA) randomized clinical trial was conducted between April and August 2025. The original trial was conducted from February 2018 to February 2023 at 185 sites in North America. From 1015 randomized patients with a recent cryptogenic stroke and atrial cardiopathy, 945 with available hypertension data were included in this analysis after exclusions for missing blood pressure and echocardiography data.<\/jats:p>\n <\/jats:sec>\n \n Interventions<\/jats:title>\n Apixaban, 5 mg or 2.5 mg, twice daily vs aspirin, 81 mg, once daily.<\/jats:p>\n <\/jats:sec>\n \n Main Outcomes and Measures<\/jats:title>\n The primary outcome was recurrent ischemic stroke or systemic embolism. Hypertension with high-risk features was defined as systolic blood pressure \u2265160 mm Hg at enrollment, left ventricular hypertrophy on echocardiography, or both. Cox proportional hazards models evaluated treatment interaction with hypertension with high-risk features and estimated hazard ratios within hypertension with high-risk features subgroups.<\/jats:p>\n <\/jats:sec>\n \n Results<\/jats:title>\n Among 945 patients (mean [SD] age, 68.0 [10.8] years; 513 [54.3%] female), 351 (37.1%) met criteria for hypertension with high-risk features. Over a median (IQR) follow-up of 1.6 (0.7-3.0) years within the analytic cohort, 67 patients experienced a recurrent ischemic stroke or systemic embolism. A significant interaction between hypertension with high-risk features and antithrombotic treatment was observed. In 594 patients without hypertension with high-risk features, apixaban was associated with lower risk compared to aspirin (hazard ratio [HR], 0.43; 95% CI, 0.22-0.85; annualized rate difference: \u22123.4%), whereas no significant association was observed in patients with hypertension with high-risk features (HR, 1.68; 95% CI, 0.78-3.62; annualized rate difference: 2.4%).<\/jats:p>\n <\/jats:sec>\n \n Conclusions and Relevance<\/jats:title>\n The findings in this study indicate that hypertension with high-risk features may be associated with modifications in the effect of antithrombotic treatment in patients with cryptogenic stroke. An unappreciated inclusion of strokes due to hypertensive arteriopathy may account for the lack of benefit with anticoagulation in prior trials of embolic stroke of undetermined source.<\/jats:p>\n <\/jats:sec>\n \n Trial Registration<\/jats:title>\n \n ClinicalTrials.gov Identifier:\n NCT03192215<\/jats:ext-link>\n <\/jats:p>\n <\/jats:sec>","DOI":"10.1001\/jamaneurol.2026.0855","type":"journal-article","created":{"date-parts":[[2026,4,20]],"date-time":"2026-04-20T15:30:40Z","timestamp":1776699040000},"page":"573","source":"Crossref","is-referenced-by-count":0,"title":["Hypertension With High-Risk Features in Cryptogenic Stroke"],"prefix":"10.1001","volume":"83","author":[{"given":"Mohamed","family":"Ridha","sequence":"first","affiliation":[{"name":"Department of Neurology, The Ohio State University, Columbus"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Raed","family":"Hailat","sequence":"additional","affiliation":[{"name":"Department of Neurology, The Ohio State University, Columbus"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Robert","family":"Stanton","sequence":"additional","affiliation":[{"name":"Department of Neurology, University of Cincinnati, Cincinnati, Ohio"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alexander E.","family":"Merkler","sequence":"additional","affiliation":[{"name":"Department of Neurology, Weill Cornell Medical Center, New York, New York"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mitchell S. V.","family":"Elkind","sequence":"additional","affiliation":[{"name":"Department of Neurology, Vagelos College of Physicians and Surgeons, Columbia University, New York, New York"},{"name":"Department of Epidemiology, Mailman School of Public Health, Columbia University, New York, New York"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"suffix":"Jr","given":"W. T.","family":"Longstreth","sequence":"additional","affiliation":[{"name":"Department of Neurology, University of Washington, Seattle"},{"name":"Department of Epidemiology, University of Washington, Seattle"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David L.","family":"Tirschwell","sequence":"additional","affiliation":[{"name":"Department of Neurology, University of Washington, Seattle"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Richard A.","family":"Kronmal","sequence":"additional","affiliation":[{"name":"Department of Biostatistics, University of Washington, Seattle"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yousef","family":"Hannawi","sequence":"additional","affiliation":[{"name":"Department of Neurology, The Ohio State University, Columbus"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hooman","family":"Kamel","sequence":"additional","affiliation":[{"name":"Department of Neurology, Weill Cornell Medical Center, New York, New York"},{"name":"Deputy Editor, JAMA Neurology"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"James","family":"Burke","sequence":"additional","affiliation":[{"name":"Department of Neurology, The Ohio State University, Columbus"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daniel","family":"Woo","sequence":"additional","affiliation":[{"name":"Department of Neurology, State University of New York at Buffalo, Buffalo"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"10","reference":[{"issue":"7","key":"noi260019r1","doi-asserted-by":"publisher","first-page":"e364","DOI":"10.1161\/STR.0000000000000375","article-title":"2021 Guideline for the prevention of stroke in patients with stroke and transient ischemic attack: a guideline from the American Heart Association\/American Stroke Association.","volume":"52","author":"Kleindorfer","year":"2021","journal-title":"Stroke"},{"issue":"3","key":"noi260019r2","doi-asserted-by":"publisher","first-page":"527","DOI":"10.1161\/CIRCRESAHA.116.308447","article-title":"Cryptogenic stroke: research and practice.","volume":"120","author":"Yaghi","year":"2017","journal-title":"Circ Res"},{"issue":"7","key":"noi260019r3","doi-asserted-by":"publisher","first-page":"855","DOI":"10.1001\/jamaneurol.2019.0591","article-title":"Tailoring the approach to embolic stroke of undetermined source: a review.","volume":"76","author":"Kamel","year":"2019","journal-title":"JAMA Neurol"},{"issue":"20","key":"noi260019r4","doi-asserted-by":"publisher","first-page":"1906","DOI":"10.1056\/NEJMoa1813959","article-title":"Dabigatran for prevention of stroke after embolic stroke of undetermined source.","volume":"380","author":"Diener","year":"2019","journal-title":"N Engl J Med"},{"issue":"23","key":"noi260019r5","doi-asserted-by":"publisher","first-page":"2191","DOI":"10.1056\/NEJMoa1802686","article-title":"Rivaroxaban for stroke prevention after embolic stroke of undetermined source.","volume":"378","author":"Hart","year":"2018","journal-title":"N Engl J Med"},{"issue":"7","key":"noi260019r6","doi-asserted-by":"publisher","first-page":"573","DOI":"10.1001\/jama.2023.27188","article-title":"Apixaban to prevent recurrence after cryptogenic stroke in patients with atrial cardiopathy: the ARCADIA randomized clinical trial.","volume":"331","author":"Kamel","year":"2024","journal-title":"JAMA"},{"issue":"4","key":"noi260019r7","doi-asserted-by":"publisher","first-page":"429","DOI":"10.1016\/S1474-4422(13)70310-7","article-title":"Embolic strokes of undetermined source: the case for a new clinical construct.","volume":"13","author":"Hart","year":"2014","journal-title":"Lancet Neurol"},{"issue":"2","key":"noi260019r8","doi-asserted-by":"publisher","first-page":"207","DOI":"10.1177\/1747493018799981","article-title":"The atrial cardiopathy and antithrombotic drugs in prevention after cryptogenic stroke randomized trial: rationale and methods.","volume":"14","author":"Kamel","year":"2019","journal-title":"Int J Stroke"},{"key":"noi260019r9","doi-asserted-by":"publisher","DOI":"10.1136\/bmj-2024-081124","article-title":"CONSORT 2025 explanation and elaboration: updated guideline for reporting randomised trials.","volume":"389","author":"Hopewell","year":"2025","journal-title":"BMJ"},{"issue":"12","key":"noi260019r10","doi-asserted-by":"publisher","first-page":"1874","DOI":"10.1097\/HJH.0000000000003480","article-title":"2023 ESH guidelines for the management of arterial hypertension the task force for the management of arterial hypertension of the European Society of Hypertension: endorsed by the International Society of Hypertension (ISH) and the European Renal Association (ERA).","volume":"41","author":"Mancia","year":"2023","journal-title":"J Hypertens"},{"issue":"1","key":"noi260019r11","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.echo.2014.10.003","article-title":"Recommendations for cardiac chamber quantification by echocardiography in adults: an update from the American Society of Echocardiography and the European Association of Cardiovascular Imaging.","volume":"28","author":"Lang","year":"2015","journal-title":"J Am Soc Echocardiogr"},{"issue":"12","key":"noi260019r12","doi-asserted-by":"publisher","first-page":"2617","DOI":"10.1681\/ASN.2009010025","article-title":"Change in estimated GFR associates with coronary heart disease and mortality.","volume":"20","author":"Matsushita","year":"2009","journal-title":"J Am Soc Nephrol"},{"issue":"19","key":"noi260019r13","doi-asserted-by":"publisher","first-page":"1737","DOI":"10.1056\/NEJMoa2102953","article-title":"New creatinine- and cystatin c-based equations to estimate GFR without race.","volume":"385","author":"Inker","year":"2021","journal-title":"N Engl J Med"},{"issue":"3","key":"noi260019r14","doi-asserted-by":"crossref","first-page":"220","DOI":"10.1001\/jamaneurol.2024.4838","article-title":"Apixaban to prevent covert infarcts after cryptogenic stroke in patients with atrial cardiopathy: a secondary analysis of the ARCADIA randomized clinical trial.","volume":"82","author":"Lansberg","year":"2025","journal-title":"JAMA Neurol"},{"issue":"8","key":"noi260019r15","doi-asserted-by":"publisher","first-page":"871","DOI":"10.1212\/WNL.32.8.871","article-title":"Lacunar strokes and infarcts: a review.","volume":"32","author":"Fisher","year":"1982","journal-title":"Neurology"},{"issue":"4","key":"noi260019r16","doi-asserted-by":"publisher","first-page":"891","DOI":"10.1161\/01.STR.0000157949.34986.30","article-title":"Are lacunar strokes really different? a systematic review of differences in risk factor profiles between lacunar and nonlacunar infarcts.","volume":"36","author":"Jackson","year":"2005","journal-title":"Stroke"},{"issue":"8","key":"noi260019r17","doi-asserted-by":"publisher","first-page":"2050","DOI":"10.1161\/01.STR.0000079818.08343.8C","article-title":"Differences in vascular risk factors between etiological subtypes of ischemic stroke: importance of population-based studies.","volume":"34","author":"Schulz","year":"2003","journal-title":"Stroke"},{"issue":"4","key":"noi260019r18","doi-asserted-by":"publisher","first-page":"624","DOI":"10.1161\/STROKEAHA.109.558809","article-title":"Differing risk factor profiles of ischemic stroke subtypes: evidence for a distinct lacunar arteriopathy?","volume":"41","author":"Jackson","year":"2010","journal-title":"Stroke"},{"issue":"10","key":"noi260019r19","doi-asserted-by":"publisher","first-page":"2493","DOI":"10.1161\/01.STR.0000239694.19359.88","article-title":"Risk factors for ischemic stroke subtypes: the Atherosclerosis Risk in Communities study.","volume":"37","author":"Ohira","year":"2006","journal-title":"Stroke"},{"issue":"6","key":"noi260019r20","doi-asserted-by":"publisher","first-page":"1050","DOI":"10.1007\/s12975-023-01195-9","article-title":"Cerebral small vessel disease: a review of the pathophysiological mechanisms.","volume":"15","author":"Hannawi","year":"2024","journal-title":"Transl Stroke Res"},{"issue":"7","key":"noi260019r21","doi-asserted-by":"publisher","first-page":"602","DOI":"10.1016\/S1474-4422(23)00131-X","article-title":"Neuroimaging standards for research into small vessel disease-advances since 2013.","volume":"22","author":"Duering","year":"2023","journal-title":"Lancet Neurol"},{"issue":"16","key":"noi260019r22","doi-asserted-by":"publisher","first-page":"1407","DOI":"10.1161\/CIRCULATIONAHA.114.011147","article-title":"Cause and mechanisms of intracranial atherosclerosis.","volume":"130","author":"Ritz","year":"2014","journal-title":"Circulation"},{"issue":"9921","key":"noi260019r23","doi-asserted-by":"publisher","first-page":"984","DOI":"10.1016\/S0140-6736(13)61088-0","article-title":"Intracranial atherosclerosis.","volume":"383","author":"Qureshi","year":"2014","journal-title":"Lancet"},{"issue":"1","key":"noi260019r24","doi-asserted-by":"publisher","first-page":"491","DOI":"10.1186\/s12872-020-01736-2","article-title":"Diagnostic performance of clinic and home blood pressure measurements compared with ambulatory blood pressure: a systematic review and meta-analysis.","volume":"20","author":"Karnjanapiboonwong","year":"2020","journal-title":"BMC Cardiovasc Disord"},{"issue":"4","key":"noi260019r25","doi-asserted-by":"publisher","first-page":"374","DOI":"10.1016\/S1474-4422(14)70031-6","article-title":"Acute post-stroke blood pressure relative to premorbid levels in intracerebral haemorrhage versus major ischaemic stroke: a population-based study.","volume":"13","author":"Fischer","year":"2014","journal-title":"Lancet Neurol"},{"issue":"3","key":"noi260019r26","doi-asserted-by":"publisher","first-page":"505","DOI":"10.1161\/HYPERTENSIONAHA.121.18502","article-title":"Hypertension-mediated organ damage: prevalence, correlates, and prognosis in the community.","volume":"79","author":"Vasan","year":"2022","journal-title":"Hypertension"},{"issue":"17","key":"noi260019r27","doi-asserted-by":"publisher","first-page":"2039","DOI":"10.1161\/hc4201.097944","article-title":"Left ventricular hypertrophy as an independent predictor of acute cerebrovascular events in essential hypertension.","volume":"104","author":"Verdecchia","year":"2001","journal-title":"Circulation"}],"container-title":["JAMA Neurology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/jamanetwork.com\/journals\/jamaneurology\/articlepdf\/2847758\/jamaneurology_ridha_2026_oi_260019_1780343312.98015.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,6,8]],"date-time":"2026-06-08T15:00:30Z","timestamp":1780930830000},"score":1,"resource":{"primary":{"URL":"https:\/\/jamanetwork.com\/journals\/jamaneurology\/fullarticle\/2847758"}},"subtitle":["An Exploratory Analysis of the ARCADIA Randomized Clinical Trial"],"short-title":[],"issued":{"date-parts":[[2026,6,1]]},"references-count":27,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2026,6,1]]}},"URL":"https:\/\/doi.org\/10.1001\/jamaneurol.2026.0855","relation":{},"ISSN":["2168-6149"],"issn-type":[{"value":"2168-6149","type":"print"}],"subject":[],"published":{"date-parts":[[2026,6,1]]}}}